About Rose Pharma
Rose Pharma is a clinical phase biopharmaceutical company focusing on development of novel treatments
for irritable bowel syndrome (IBS) and functional dyspepsia (FD), disorders which affect 10-20% of the
general population and which are large unmet clinical needs.
The platform technology is based around glucagon-like peptide-1 (GLP-1).
|
|
| May 2010
|
|
Results from the Rose sponsored study on the natural history of pain attacks were presented at DDW 2010 in two talks by Prof Lin Chang (UCLA) and Prof Per Hellstrom (Uppsala). |
|
Read more
|
|
|
